Should We Consider Microbiota-Based Interventions as a Novel Therapeutic Strategy for Schizophrenia? A Systematic Review and Meta-Analysis DOI Creative Commons
Lucas Hassib,

Alexandre Kanashiro,

João Francisco Cordeiro Pedrazzi

et al.

Brain Behavior & Immunity - Health, Journal Year: 2024, Volume and Issue: 43, P. 100923 - 100923

Published: Dec. 11, 2024

Schizophrenia is a chronic psychiatric disorder characterized by variety of symptoms broadly categorized into positive, negative, and cognitive domains. Its etiology multifactorial, involving complex interplay genetic, neurobiological, environmental factors, its neurobiology associated with abnormalities in different neurotransmitter systems. Due to this multifactorial neurobiology, leading wide heterogeneity clinical presentations, current antipsychotic treatments face challenges, underscoring the need for novel therapeutic approaches. Recent studies have revealed differences gut microbiome individuals schizophrenia compared healthy controls, establishing an intricate link between gastrointestinal health, suggesting that microbiota-targeted interventions could help alleviate symptoms. Therefore, meta-analysis investigates whether microbiota manipulation can ameliorate psychotic outcomes patients receiving pharmacological treatment. Nine (n = 417 participants) were selected from 81 records, comprising seven randomized controlled trials two open-label studies, all low risk bias, included systematic review meta-analysis. The overall combined effect size indicated significant symptom improvement following treatment (Hedges' g 0.48, 95% CI 0.09 0.88, p 0.004, I2 62.35%). However, according Hedges' criteria, was small (approaching moderate), study moderate based on criteria. This also discusses preclinical elucidate neural, immune, metabolic pathways which manipulation, particularly Lactobacillus Bifidobacterium genera, may exert beneficial effects via gut-brain axis. Finally, we address main confounding factors identified our review, highlight key limitations, offer recommendations guide future high-quality larger participant cohorts explore microbiome-based therapies as primary or adjunctive schizophrenia.

Language: Английский

Should We Consider Microbiota-Based Interventions as a Novel Therapeutic Strategy for Schizophrenia? A Systematic Review and Meta-Analysis DOI Creative Commons
Lucas Hassib,

Alexandre Kanashiro,

João Francisco Cordeiro Pedrazzi

et al.

Brain Behavior & Immunity - Health, Journal Year: 2024, Volume and Issue: 43, P. 100923 - 100923

Published: Dec. 11, 2024

Schizophrenia is a chronic psychiatric disorder characterized by variety of symptoms broadly categorized into positive, negative, and cognitive domains. Its etiology multifactorial, involving complex interplay genetic, neurobiological, environmental factors, its neurobiology associated with abnormalities in different neurotransmitter systems. Due to this multifactorial neurobiology, leading wide heterogeneity clinical presentations, current antipsychotic treatments face challenges, underscoring the need for novel therapeutic approaches. Recent studies have revealed differences gut microbiome individuals schizophrenia compared healthy controls, establishing an intricate link between gastrointestinal health, suggesting that microbiota-targeted interventions could help alleviate symptoms. Therefore, meta-analysis investigates whether microbiota manipulation can ameliorate psychotic outcomes patients receiving pharmacological treatment. Nine (n = 417 participants) were selected from 81 records, comprising seven randomized controlled trials two open-label studies, all low risk bias, included systematic review meta-analysis. The overall combined effect size indicated significant symptom improvement following treatment (Hedges' g 0.48, 95% CI 0.09 0.88, p 0.004, I2 62.35%). However, according Hedges' criteria, was small (approaching moderate), study moderate based on criteria. This also discusses preclinical elucidate neural, immune, metabolic pathways which manipulation, particularly Lactobacillus Bifidobacterium genera, may exert beneficial effects via gut-brain axis. Finally, we address main confounding factors identified our review, highlight key limitations, offer recommendations guide future high-quality larger participant cohorts explore microbiome-based therapies as primary or adjunctive schizophrenia.

Language: Английский

Citations

0